What Alpha-1 Augmentation treats.
- Alpha-1 antitrypsin deficiency (genetic)
- Alpha-1 related emphysema and chronic obstructive pulmonary disease
- Slowing the progression of lung tissue damage in deficient patients
The mechanism.
Alpha-1 antitrypsin is a protein produced by the liver that protects lung tissue from damage caused by neutrophil elastase. Patients with alpha-1 antitrypsin deficiency don’t produce enough of this protective protein, leading to early-onset emphysema. Augmentation therapy replaces the missing protein with weekly IV infusions of human-derived alpha-1 antitrypsin, raising blood and lung levels into the protective range.
Your Alpha-1 Augmentation infusion experience.
Alpha-1 augmentation is a weekly IV infusion typically lasting 30 to 60 minutes depending on dose and product. Treatment is lifelong — the goal is to slow lung function decline rather than reverse damage that has already occurred. Brand-name products (Aralast NP, Prolastin-C, Glassia) are clinically equivalent; your prescribing pulmonologist may select based on availability or insurance preference. Many patients work or run errands the same day.
Insurance & out-of-pocket cost.
Alpha-1 Augmentation is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.